Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Dexamethasone + Felzartamab + Pomalidomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Felzartamab||MOR03087|TJ202|MOR202||CD38 Antibody 17||Felzartamab (MOR202) is a monoclonal antibody that binds CD38, potentially resulting in increased cytoxicity against CD38-expressing tumor cells and tumor cell lysis (PMID: 29654274, PMID: 32171061).|
|Pomalidomide||Pomalyst||CC-4047||Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|